Tuis207940 • KRX
add
Samsung Biologics Co Ltd
Vorige sluiting
₩1 116 000,00
Dagwisseling
₩1 110 000,00 - ₩1 145 000,00
Jaarwisseling
₩721 000,00 - ₩1 209 000,00
Markkapitalisasie
79,71 bn KRW
Gemiddelde volume
76,58 k
P/V-verhouding
73,58
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (KRW) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 1,26 bn | 17,04% |
Bedryfskoste | 334,17 mjd | 87,16% |
Netto inkomste | 321,49 mjd | 10,60% |
Netto winsgrens | 25,59 | -5,50% |
Wins per aandeel | 4,52 k | 10,60% |
EBITDA | 476,48 mjd | -3,14% |
Effektiewe belastingkoers | 14,04% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (KRW) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 1,33 bn | -35,26% |
Totale bates | 17,34 bn | 8,04% |
Totale aanspreeklikheid | 6,43 bn | 3,47% |
Totale ekwiteit | 10,90 bn | — |
Uitstaande aandele | 71,17 m | — |
Prys om te bespreek | 7,28 | — |
Opbrengs op bates | 4,88% | — |
Opbrengs op kapitaal | 6,80% | — |
Kontantvloei
Netto kontantverandering
| (KRW) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 321,49 mjd | 10,60% |
Kontant van bedrywe | 389,56 mjd | -53,23% |
Kontant van beleggings | -1,07 bn | -138,92% |
Kontant van finansiering | 514,35 mjd | 280,15% |
Netto kontantverandering | -149,00 mjd | -267,89% |
Beskikbare kontantvloei | -30,00 mjd | -107,16% |
Meer oor
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
HUB
Gestig
2011
Webwerf
Werknemers
4 744
